FDA approval of nonavalent HPV vaccine adds new tool to eradicate cervical cancer
It is estimated that the seven “high-risk” HPV types found in the nonavalent vaccine can potentially prevent over 90 percent of cervical cancers and a similarly high number of other HPV-associated cancers of the vulva, vagina, anus, penis, and some head and neck cancers. “As the healthcare providers for women who suffer from cervical and lower genital tract cancers, members of the SGO have always been advocates for the primary prevention of cervical and other HPV-related cancers,” said SGO President Richard R…